Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Toyoaki Hida"'
Autor:
Testuya Mitsudomi, Shingo Matsumoto, Hidehito Horinouchi, Fumihiko Hirai, Takashi Seto, Katsuyuki Hotta, Kota Tokushige, Masataka Yonemura, Masayuki Ito, Young Hak Kim, Koichi Ayukawa, Makoto Nishio, Toyoaki Hida, Makoto Maemondo, Masayuki Takeda
Publikováno v:
Cancer Science
Clinical experience of ceritinib in patients who progressed on alectinib is limited. In this prospective phase II study, we evaluated the activity of ceritinib in alectinib-pretreated patients with anaplastic lymphoma kinase (ALK)-rearranged metastat
Autor:
Miyako Satouchi, Kazuhiko Nakagawa, Toyoaki Hida, Takashi Seto, Yuichiro Ohe, Katsuyuki Hotta, Makoto Nishio, Masahiro Tatsuno, Takashi Asakawa, Tadashi Shimada, Tomohiro Tanaka, Toshiaki Takahashi, Tomohide Tamura, Koji Takeda
Publikováno v:
Cancer Science
Summary We report pharmacokinetics, efficacy, and safety data for a new 150 mg alectinib capsule in ALK+ non-small-cell lung cancer in a multicenter, open-label pharmacologic study (JP28927). Eligible patients (≥20 years, locally advanced/metastati
Autor:
Junichi Shimizu, Tatsuya Yoshida, Yukinori Sakao, Yoshitsugu Horio, Yasushi Yatabe, Yuko Oya, Toyoaki Hida, Hiroaki Kuroda, Kosuke Tanaka
Publikováno v:
Journal of Clinical Oncology. 34:3383-3389
Purpose Anaplastic lymphoma kinase (ALK) rearrangement–positive non–small-cell lung cancers can be effectively treated with an ALK tyrosine kinase inhibitor (TKI) such as crizotinib, but the response magnitude and duration are heterogeneous. Seve
Autor:
Makoto Nishio, Jie Zhang, Chetachi Emeremni, Myung-Ju Ahn, Lucio Crinò, David R. Spigel, Tony Mok, Toyoaki Hida, Enriqueta Felip, Filippo de Marinis, Massimiliano Quadrigli, Giorgio V. Scagliotti, Alice T. Shaw, Fabrice Branle, Heather A. Wakelee, Harry J.M. Groen
Publikováno v:
Journal of Clinical Oncology, 34(24), 2866-2878. AMER SOC CLINICAL ONCOLOGY
Purpose Phase I data (ASCEND-1) showed ceritinib efficacy in patients with ALK-rearranged non–small-cell lung cancer (NSCLC), regardless of brain metastases status and with or without prior therapy with an inhibitor of the ALK protein. Data are pre
Autor:
Miyako Satouchi, Masayuki Ito, Katsuyuki Kiura, Fumio Imamura, Toyoaki Hida, Shingo Matsumoto, Yasuhito Fujisaka, Makoto Nishio, Kazuhiko Nakagawa, Hiroshi Kagamu, Takayasu Kurata, Isamu Okamoto, Kota Tokushige, Ben Hatano, Mitsuhiro Takenoyama
Publikováno v:
Japanese Journal of Clinical Oncology
This subgroup analysis of ASCEND-5 study demonstrated better efficacy of ceritinib compared with the standard second-line chemotherapy in chemotherapy- and crizotinib-pretreated Japanese patients with ALK-rearranged NSCLC.
Background In the glob
Background In the glob
Autor:
Toyoaki Hida, Takehiro Uemura
Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive non-small-cell lung cancer (NSCLC). We investigated alectinib as compared with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64498c45ddbb46ef0d50d026621a7f9a
https://europepmc.org/articles/PMC5690958/
https://europepmc.org/articles/PMC5690958/
Autor:
Kazuhiko Nakagawa, Makoto Nishio, Takashi Seto, Ben Hatano, Haruyasu Murakami, Shingo Matsumoto, Kota Tokushige, Hiroshi Nokihara, Toyoaki Hida, Miyako Satouchi, Katsuyuki Kiura
Publikováno v:
Japanese journal of clinical oncology. 47(7)
Introduction Anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer is sensitive to tyrosine kinase inhibitors; however, resistance can develop. Data are presented from the phase II trial (ASCEND-2) evaluating efficacy and safety in a
Autor:
Takashi Seto, Nobuyuki Yamamoto, Fumio Imamura, Tomohide Tamura, Hiroshi Nokihara, Ryoichi Asabe, Hiroshige Yoshioka, Takashi Asakawa, Yuichi Takiguchi, Kazuhiko Nakagawa, Tetsuya Mitsudomi, Satoshi Watanabe, Masashi Kondo, Takehito Shukuya, Koichi Goto, Toyoaki Hida, Koichi Azuma, Toshiyuki Kozuki, Miyako Satouchi, Katsuyuki Hotta, Young Hak Kim, Tomohiro Tanaka, Makoto Nishio
Publikováno v:
Lancet (London, England). 390(10089)
Alectinib, a potent, highly selective, CNS-active inhibitor of anaplastic lymphoma kinase (ALK), showed promising efficacy and tolerability in the single-arm phase 1/2 AF-001JP trial in Japanese patients with ALK-positive non-small-cell lung cancer.
Autor:
Tomohiro Tanaka, Akira Inoue, Kengo Takeuchi, Nobuyuki Yamamoto, Kazuhiko Nakagawa, Katsuyuki Kiura, Yuichiro Ohe, Tadashi Shimada, Makoto Nishio, Toyoaki Hida, Hiroshige Yoshioka, Tomohide Tamura, Naoyuki Nogami, Masao Harada, Makoto Maemondo, Takashi Seto
Publikováno v:
The Lancet Oncology. 14:590-598
Summary Background Currently, crizotinib is the only drug that has been approved for treatment of ALK -rearranged non-small-cell lung cancer (NSCLC). We aimed to study the activity and safety of CH5424802, a potent, selective, and orally available AL
Publikováno v:
Anti-cancer drugs. 27(6)
Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) have shown promising clinical activity in the treatment of non-small-cell lung cancer (NSCLC) that harbors ALK rearrangement. The next-generation ALK-TKI, alectinib, has been reported